Leeds, UK, July 29, 2021 – 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived
Leeds, UK, July 29, 2021 – 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived
Leeds, UK, July 26, 2021 – 4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived
Huge honour to support Ride4Rahma Challenging 70-mile ride from Dewsbury to the historic city of York to raise funds for ongoing projects in the Balkans registration charity, please donating here & share
4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T
The stock market story featuring two like-minded investors Peter Pan @PanPeterS5 & Simon Huckle @sihuckle discuss their times on the market. Well done boys @JtZulu
4D pharma to Present at the Microbiome Movement Drug Development Summit
Huge honour to support Ride4Rahma Challenging 70-mile ride from Dewsbury to the historic city of York to raise funds for ongoing projects in the Balkans registration charity, please donating here & share
4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update
Been a good week for company updates, we interviewed Alien Metals Ltd who are delivering news on a weekly basis right now with the Phase 2 drilling commences on Hancock
4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syndrome
4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestive Disease Week (DDW) 2021
Leeds, UK, April 19, 2021 – 4D pharma plc (AIM: DDDD; NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug